These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31532058)

  • 1. A gain of function paradox: Targeted therapy for glioblastoma associated with abnormal NHE9 expression.
    Pall AE; Juratli L; Guntur D; Bandyopadhyay K; Kondapalli KC
    J Cell Mol Med; 2019 Nov; 23(11):7859-7872. PubMed ID: 31532058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-135a regulates NHE9 to inhibit proliferation and migration of glioblastoma cells.
    Gomez Zubieta DM; Hamood MA; Beydoun R; Pall AE; Kondapalli KC
    Cell Commun Signal; 2017 Dec; 15(1):55. PubMed ID: 29268774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma.
    Kondapalli KC; Llongueras JP; Capilla-González V; Prasad H; Hack A; Smith C; Guerrero-Cázares H; Quiñones-Hinojosa A; Rao R
    Nat Commun; 2015 Feb; 6():6289. PubMed ID: 25662504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Na
    Beydoun R; Hamood MA; Gomez Zubieta DM; Kondapalli KC
    J Biol Chem; 2017 Mar; 292(10):4293-4301. PubMed ID: 28130443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endosomal pH regulator NHE9 is a driver of stemness in glioblastoma.
    Ko M; Makena MR; Schiapparelli P; Suarez-Meade P; Mekile AX; Lal B; Lopez-Bertoni H; Kozielski KL; Green JJ; Laterra J; Quiñones-Hinojosa A; Rao R
    PNAS Nexus; 2022 Mar; 1(1):pgac013. PubMed ID: 35387234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sodium proton exchanger NHE9 regulates phagosome maturation and bactericidal activity in macrophages.
    Shamroukh HS; Lone N; Akhtar M; Altayib A; Sutliff S; Kassem Z; Tripathy SK; Kondapalli KC
    J Biol Chem; 2022 Aug; 298(8):102150. PubMed ID: 35716776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaffolds biomimicking macrophages for a glioblastoma NIR-Ib imaging guided photothermal therapeutic strategy by crossing Blood-Brain Barrier.
    Lai J; Deng G; Sun Z; Peng X; Li J; Gong P; Zhang P; Cai L
    Biomaterials; 2019 Aug; 211():48-56. PubMed ID: 31085358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of disease-associated SLC9A9 mutations on protein-protein interaction networks: implications for molecular mechanisms for ADHD and autism.
    Zhang-James Y; Vaudel M; Mjaavatten O; Berven FS; Haavik J; Faraone SV
    Atten Defic Hyperact Disord; 2019 Mar; 11(1):91-105. PubMed ID: 30927234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Application of Ultrasmall Gold Nanoparticles (2 nm) Functionalized with Doxorubicin in Three-Dimensional Normal and Glioblastoma Organoid Models of the Blood-Brain Barrier.
    Kostka K; Sokolova V; El-Taibany A; Kruse B; Porada D; Wolff N; Prymak O; Seeds MC; Epple M; Atala AJ
    Molecules; 2024 May; 29(11):. PubMed ID: 38893345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging links between endosomal pH and cancer.
    Ko M; Quiñones-Hinojosa A; Rao R
    Cancer Metastasis Rev; 2020 Jun; 39(2):519-534. PubMed ID: 32253638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.
    Gao H; Xiong Y; Zhang S; Yang Z; Cao S; Jiang X
    Mol Pharm; 2014 Mar; 11(3):1042-52. PubMed ID: 24521297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma.
    Peng L; Liang Y; Zhong X; Liang Z; Tian Y; Li S; Liang J; Wang R; Zhong Y; Shi Y; Zhang X
    Int J Nanomedicine; 2020; 15():1363-1372. PubMed ID: 32184591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recent insight of applications of gold nanoparticles in glioblastoma multiforme therapy.
    Qureshi S; Anjum S; Hussain M; Sheikh A; Gupta G; Almoyad MAA; Wahab S; Kesharwani P
    Int J Pharm; 2024 Jul; 660():124301. PubMed ID: 38851411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional evaluation of autism-associated mutations in NHE9.
    Kondapalli KC; Hack A; Schushan M; Landau M; Ben-Tal N; Rao R
    Nat Commun; 2013; 4():2510. PubMed ID: 24065030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma.
    Janjua TI; Ahmed-Cox A; Meka AK; Mansfeld FM; Forgham H; Ignacio RMC; Cao Y; McCarroll JA; Mazzieri R; Kavallaris M; Popat A
    Nanoscale; 2021 Oct; 13(40):16909-16922. PubMed ID: 34533167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
    Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
    Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective glioblastoma immune sonodynamic treatment mediated by macrophage cell membrane cloaked biomimetic nanomedicines.
    Shan T; Wang W; Fan M; Bi J; He T; Sun Y; Zheng M; Yan D
    J Control Release; 2024 Jun; 370():866-878. PubMed ID: 38685386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Evaluation of Transferrin-Modified Porous Silicon Nanoparticles for Targeted Delivery of Doxorubicin to Glioblastoma.
    Luo M; Lewik G; Ratcliffe JC; Choi CHJ; Mäkilä E; Tong WY; Voelcker NH
    ACS Appl Mater Interfaces; 2019 Sep; 11(37):33637-33649. PubMed ID: 31433156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.